The “Life Sciences” cluster in Zurich and the economy to come
A study in German commissioned by Standortförderung AWA Zürich from BAK Economics tells of a district that is generous with medtech, biotech and pharmaceutical patents
The COVID-19 pandemic is putting a strain on the federal economy. In March 2020, a significant portion of public life came to a complete halt overnight.
The study “Clusterstudie Life Sciences Zürich 2021-2022” by BAK Economics (in German)
The media presentation of the study “Clusterstudie Life Sciences Zürich 2021-2022” by BAK Economics (in German)
As the infection and deaths dramatically progressed, companies had to adapt to new regulations, restrictions and requirements to protect their staff and customers from the virus.
If, in general, the Zurich economy did not suffer a greater collapse than had actually been assumed in the run-up to the outbreak, this is also due to the fact that the canton has a diversified economic system.
As far as life sciences are concerned, the city on the banks of the Limmat is an exceptionally dynamic research location, where the number of world-class patents in the medtech, biotech and pharmaceutical sectors is growing faster than anywhere else in the world.
And this is mainly due to the excellent conditions offered to university research.
The two Federal Institutes of Technology in Lausanne and Zurich are booming.
2.6 billion in value from the Zurich Innovation Park
Bern, Zurich and Aargau focus on fiscal innovation…
Insurance companies pillar of Zurich’s marketplace
Data science and the common good: ETH with the FSO
The study “Clusterstudie Life Sciences Zürich 2021/2022 Eine Studie der Standortförderung im Amt für Wirtschaft und Arbeit des Kantons Zürich”, commissioned from BAK Economics by the cantonal administration, therefore focuses on the Zurich life sciences cluster, its innovative strength in an international comparison and development forecasts drawn up on the basis of a specific scenario.
